Join
Live feed
·
INSIDERFilingvia Quantisnow
Aprea Therapeutics Inc. logo

Director Henneman John B Iii was granted 1,045 shares, increasing direct ownership by 11% to 10,229 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
APRE· Aprea Therapeutics Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track APRE (Aprea Therapeutics Inc.) and more on Quantisnow.